Table 3 Cerebrospinal fluid biomarker findings
From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Change from baseline at week 104 | Placebo | Gantenerumab 105 mg | Gantenerumab 225 mg | ||
|---|---|---|---|---|---|
Change (%), median (Q1, Q3) | Change (%), median (Q1, Q3) | p Value vs placebo | Change (%), median (Q1, Q3) | p Value vs placebo | |
Aβ42, pg/ml | n = 72 −0.85% (−15.31, 21.03) | n = 71 −1.06% (−19.33, 25.88) | 0.98 | n = 66 7.55% (−13.96, 35.09) | 0.09 |
t-tau, pg/ml | n = 72 2.04% (−4.56, 8.72) | n = 71 −1.08% (−7.65, 5.86) | 0.05 | n = 66 −2.91% (−8.54, 3.40) | 0.02 |
p-tau, pg/ml | n = 72 0.08% (−3.91, 6.49) | n = 71 −5.61% (−11.07, 0.97) | ≤ 0.001 | n = 66 −7.15% (−14.48, −2.41) | ≤ 0.001 |
Neurogranin, pg/ml | n = 65 −3.24% (−20.64, 12.27) | n = 66 −4.58% (−19.89, 10.13) | 0.79 | n = 63 −11.76% (−23.69, 6.48) | 0.18 |